<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2013-9-6-640-649</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-273</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group></article-categories><title-group><article-title>THROMBOLYSIS OR PRIMARY PCI FOR MYOCARDIAL INFARCTION WITH ST-SEGMENT ELEVATION? THE STREAM TRIAL (STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL INFARCTION)</article-title><trans-title-group xml:lang="ru"><trans-title>ТРОМБОЛИЗИС ИЛИ ПЕРВИЧНОЕ ЧРЕСКОЖНОЕ КОРОНАРНОЕ ВМЕШАТЕЛЬСТВО ПРИ ИНФАРКТЕ МИОКАРДА С ПОДЪЕМОМ ST-СЕГМЕНТА? ИССЛЕДОВАНИЕ STREAM (STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL  INFARCTION)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сулимов</surname><given-names>В. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Sulimov</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор медицинских наук, профессор, заведующий кафедрой факультетской терапии №1, директор Факультетской терапевтической клиники имени В. Н. Виноградова</p></bio><email xlink:type="simple">vsulimov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Первый Московский медицинский университет имени И.М. Сеченова, Москва</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov  First Moscow State Medical University, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>25</day><month>09</month><year>2015</year></pub-date><volume>9</volume><issue>6</issue><fpage>640</fpage><lpage>649</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Sulimov V.A., 2015</copyright-statement><copyright-year>2015</copyright-year><copyright-holder xml:lang="ru">Сулимов В.Ф.</copyright-holder><copyright-holder xml:lang="en">Sulimov V.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/273">https://www.rpcardio.online/jour/article/view/273</self-uri><abstract><p>Ambiguous data about comparability regarding clinical outcomes for prehospital thrombolysis, coupled with timely coronary angiography, and primary percutaneous coronary intervention (PCI) in the early after acute ST-segment elevation myocardial infarction (STEMI), there are now.In the STREAM trial 1892 patients with STEMI diagnosed within 3 hours after onset of symptoms, and whom it was impossible to perform primary PCI within 1 h after the first medical contact, were randomly assigned into two treatment groups: a) primary PCI b) prehospital thrombolytic therapy with bolus tenecteplase (dose decreased by half in patients aged ≥75 years) in combination with clopidogrel and enoxaparin followed by admission to the hospital, where it was possible to perform PCI. Emergency coronary angiography performed if thrombolysis failed. Coronary angiography and PCI of the infarct-related artery were performed in the period from 6 to 24 hours after randomization and thrombolytic therapy in the case of an effective thrombolysis. Primary endpoints include a composite of death, shock, congestive heart failure, or reinfarction up to 30 days.The primary endpoint occurred in 116 of 939 patients (12.4 %) of the thrombolysis group and in 135 of 943 patients (14.3%) of the primary PCI group (relative risk in the group thrombolysis 0.86, 95% confidence interval 0.68-1.09, p=0.21). Emergency angiography was required in 36.3% of patients in the thrombolysis, and the remaining patients, coronary angiography and PCI were performed at a mean of 17 hours after randomization and thrombolytic therapy. Thrombolysis group had more intracranial hemorrhages than primary PCI group (1.0% vs 0.2%, p=0.04; after correction protocol and dose reduction by half of tenecteplase in patients ≥75 years: 0.5% vs. 0.3%, p=0.45). The rate of non- intracranial bleeding in two treatment groups did not differ.Prehospital thrombolysis followed by coronary angiography and timely PCI provide effective reperfusion in patients in the early stages of STEMI that was not possible to carry out primary PCI within 1 h after the first medical contact. Nevertheless, fibrinolysis was associated with a slight increase in the risk of intracranial bleeding.</p></abstract><trans-abstract xml:lang="ru"><p>На сегодняшний день имеются противоречивые данные о том, обеспечивает ли догоспитальный тромболизис в сочетании со своевременно выполненным чрескожным коронарным вмешательством (ЧКВ) клинический исход, аналогичный результатам первичного ЧКВ в ранние сроки от начала возникновения клинической картины острого инфаркта миокарда с подъемом ST-сегмента (ИМпST).В исследовании STREAM 1892 пациентов с ИМпST, диагностированным в течение 3 ч после появления симптомов, и которым было невозможно сделать первичное ЧКВ в течение 1 ч после первого медицинского контакта, были рандомизировано распределены в две группы лечения: а) первичного ЧКВ, б) тромболитической терапии на догоспитальном этапе с помощью болюсного в/в введения тенектеплазы (доза которой уменьшалась наполовину у пациентов в возрасте ≥75 лет) в комбинации с клопидогрелом и эноксапарином с последующей госпитализацией в стационар, где было возможно выполнение ЧКВ. Если тромболизис оказывался неэффективен, больным срочно выполняли «спасительное ЧКВ». В случае эффективного тромболизиса коронарография и ЧКВ инфаркт-связанной артерии выполнялись в срок от 6 до 24 ч после рандомизации и тромболитической терапии. Первичная конечная точка включала суммарно смерть от любых причин, кардиогенный шок, застойную сердечную недостаточность, или повторный инфаркт, возникшие в течение первых 30 дней наблюдения.Первичная конечная точка была зарегистрирована у 116 из 939 пациентов (12,4%) в группе троболизиса и у 135 из 943 пациентов (14,3%) в группе первичного ЧКВ (относительный риск в группе тромболизиса 0,86; 95% доверительный интервал от 0,68 до 1,09; р=0,21). В группе тромболизиса «спасительное ЧКВ» потребовалось у 36,3% пациентов, у остальных пациентов коронарная ангиография и ЧКВ выполнялись в среднем через 17 ч после рандомизации и тромболитической терапии. В группе тромболизиса возникло больше внутричерепных кровоизлияний, чем в группе первичного ЧКВ (1,0% против 0,2%, p=0,04; после коррекции прото- кола и уменьшения дозы тенектеплазы наполовину у больных ≥75 лет – 0,5% против 0,3%, p=0,45). Частота невнутричерепных кровотечений в двух группах лечения не различалась.Догоспитальный тромболизис с последующей своевременной коронарной ангиографией и ЧКВ обеспечивал эффективную реперфузию у пациентов в ранние сроки ИМ с подъемом сегмента ST, которым было не возможно провести первичное ЧКВ в течение 1 ч после первого медицинского контакта. Тем не менее, фибринолиз был ассоциирован с небольшим увеличением риска внутричерепных кровотечений.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>острый инфаркт миокарда с подъемом ST-сегмента</kwd><kwd>фибринолиз</kwd><kwd>чрескожное коронарное вмешательство</kwd></kwd-group><kwd-group xml:lang="en"><kwd>acute ST-segment elevation myocardial infarction</kwd><kwd>fibrinolysis</kwd><kwd>percutaneous coronary intervention</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Boehringer Ingelheim; номер в ClinicalTrials.gov NCT00623623</funding-statement><funding-statement xml:lang="en">Boehringer Ingelheim; ClinicalTrials.gov number, NCT00623623</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST segment elevation. Eur Heart J 2012;33:2569-619.</mixed-citation><mixed-citation xml:lang="en">Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST segment elevation. Eur Heart J 2012;33:2569-619.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61(4): e78-e140.</mixed-citation><mixed-citation xml:lang="en">O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61(4): e78-e140.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Armstrong PW, Boden WE. Reperfusion paradox in ST-segment elevation myocardial infarction. Ann Intern Med 2011; 155:389-91</mixed-citation><mixed-citation xml:lang="en">Armstrong PW, Boden WE. Reperfusion paradox in ST-segment elevation myocardial infarction. Ann Intern Med 2011; 155:389-91</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Armstrong PW, Gershlick AH, Goldstein P, et al. Fibrinolysis or Primary PCI in ST-Segment Elevation, N Engl J Med 2013;368:1379-87</mixed-citation><mixed-citation xml:lang="en">Armstrong PW, Gershlick AH, Goldstein P, et al. Fibrinolysis or Primary PCI in ST-Segment Elevation, N Engl J Med 2013;368:1379-87</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Armstrong PW, Gershlick A, Goldstein P, et al. The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. Am Heart J 2010;160(1):30.e1-35.e1.</mixed-citation><mixed-citation xml:lang="en">Armstrong PW, Gershlick A, Goldstein P, et al. The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. Am Heart J 2010;160(1):30.e1-35.e1.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Larson DM, Duval S, Sharkey SW, et al. Safety and efficacy of a pharmacoinvasive reperfusion strate- gy in rural STelevation myocardial infarction patients with expected delays due to long-distance transfers. Eur Heart J 2012;33:1232-40.</mixed-citation><mixed-citation xml:lang="en">Larson DM, Duval S, Sharkey SW, et al. Safety and efficacy of a pharmacoinvasive reperfusion strate- gy in rural STelevation myocardial infarction patients with expected delays due to long-distance transfers. Eur Heart J 2012;33:1232-40.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Harrell FE Jr. Hmisc: Harrell Miscellaneous – R package, version 3.8-3. 2010. (http://cran.r-pro- ject.org/package=Hmisc).</mixed-citation><mixed-citation xml:lang="en">Harrell FE Jr. Hmisc: Harrell Miscellaneous – R package, version 3.8-3. 2010. (http://cran.r-pro- ject.org/package=Hmisc).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Assessment of the Safety and Efﬁcacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 2006;367:569-78.</mixed-citation><mixed-citation xml:lang="en">Assessment of the Safety and Efﬁcacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 2006;367:569-78.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Le May MR, Wells GA, Labinaz M, et al. Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). J Am Coll Cardiol 2005;46:417-24.</mixed-citation><mixed-citation xml:lang="en">Le May MR, Wells GA, Labinaz M, et al. Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). J Am Coll Cardiol 2005;46:417-24.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Armstrong PW, WEST Steering Committee. A comparison of pharma- cologic therapy with/without timely coronary intervention vs primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Eur Heart J 2006;27:1530-8.</mixed-citation><mixed-citation xml:lang="en">Armstrong PW, WEST Steering Committee. A comparison of pharma- cologic therapy with/without timely coronary intervention vs primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Eur Heart J 2006;27:1530-8.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Cantor W, Fitchett D, Borgundvaag B, et al., for the TRANSFER-AMI Trial Investigators. Routine Early Angioplasty after Fibrinolysis for Acute Myocardial Infarction. N Engl J Med 2009; 360 (26):2705-18.</mixed-citation><mixed-citation xml:lang="en">Cantor W, Fitchett D, Borgundvaag B, et al., for the TRANSFER-AMI Trial Investigators. Routine Early Angioplasty after Fibrinolysis for Acute Myocardial Infarction. N Engl J Med 2009; 360 (26):2705-18.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Fernandez-Aviles F, Alonso JJ, Pena G, et al. Primary angioplasty vs early routine post-ﬁbrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial. Eur Heart J 2007;28:949-60.</mixed-citation><mixed-citation xml:lang="en">Fernandez-Aviles F, Alonso JJ, Pena G, et al. Primary angioplasty vs early routine post-ﬁbrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial. Eur Heart J 2007;28:949-60.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Boehmer E, Hoffmann P, Abdelnoor M, et al. Efficacy and Safety of Immediate Angioplasty Versus Ischemia-Guided Management After Thrombolysis in Acute Myocardial Infarction in Areas With Very Long Transfer Distances. Results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST- Elevation Myocardial Infarction) J Am Coll Cardiol 2010; 55:102-10.</mixed-citation><mixed-citation xml:lang="en">Boehmer E, Hoffmann P, Abdelnoor M, et al. Efficacy and Safety of Immediate Angioplasty Versus Ischemia-Guided Management After Thrombolysis in Acute Myocardial Infarction in Areas With Very Long Transfer Distances. Results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST- Elevation Myocardial Infarction) J Am Coll Cardiol 2010; 55:102-10.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003; 349:733-42.</mixed-citation><mixed-citation xml:lang="en">Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003; 349:733-42.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Kaul S, Diamond GA, Weintraub WS. Trials and tribulations of non-inferiority: the ximelagatran experience. J Am Coll Cardiol 2005;46:1986-95.</mixed-citation><mixed-citation xml:lang="en">Kaul S, Diamond GA, Weintraub WS. Trials and tribulations of non-inferiority: the ximelagatran experience. J Am Coll Cardiol 2005;46:1986-95.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
